Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 23, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Graft Versus Host DiseaseOcular Surface DiseaseoGVHDOcular Graft vs Host DiseaseBrimonidine TartrateLubricant Eye DropsOphthalmic SolutionsGraft vs Host Disease
Interventions
DRUG

Brimonidine Tartrate

Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.

DRUG

Placebos

Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.

Trial Locations (13)

15213

Univeristy of Pittsburgh Medical Center Eye Center, Pittsburgh

19104

University of Penn Scheie Eye Institute,, Philadelphia

27708

Duke University Medical Center, Durham

30322

Emory Eye Center, Atlanta

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University, Columbus

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

53705

University of Wisconsin Dept. of Ophthalmology and Visual Sciences, Madison

66208

University of Kansas Medical Center, Prairie Village

85054

Mayo Clinic, Phoenix

94303

Byers Eye Institute at Stanford University, Palo Alto

Oregon

"OHSU Casey Eye Institute , Cornea Division"

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocugen

INDUSTRY